A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist

Nature Medicine

Volumn 13, Issue 9, 2007, Pages 1108-1113

  Wilkinson, Ian R ^a   Ferrandis, Eric ^b   Artymiuk, Peter J ^c   Teillot, Marc ^b   Soulard, Chantal ^b   Touvay, Caroline ^b   Pradhananga, Sarbendra L ^a   Justice, Sue ^a   Wu, Zida ^d   Leung, Kin C ^e   Strasburger, Christian J ^d   Sayers, Jon R ^c   Ross, Richard J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Institut Henri Beaufour   (France)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; HYBRID PROTEIN; LIGAND RECEPTOR FUSION; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT;

ANIMALS; DIMERIZATION; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; HYPOPHYSECTOMY; LIGANDS; MODELS, MOLECULAR; MUTANT PROTEINS; PROTEIN CONFORMATION; RATS; RECEPTORS, SOMATOTROPIN;

MAMMALIA; RATTUS;

EID: 34948897971     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1610     Document Type: Article

References (27)

1. Woodhouse, L.J., Mukherjee, A., Shalet, S.M. & Ezzat, S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr. Rev. 27, 287-317 (2006).
2. Clark, R. et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271, 21969-21977 (1996).
3. Cook, D.M. et al. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. J. Clin. Endocrinol. Metab. 87, 4508-4514 (2002).
4. Reiter, E.O. et al. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J. Clin. Endocrinol. Metab. 86, 4700-4706 (2001).
5. Jostel, A., Mukherjee, A., Alenfall, J., Smethurst, L. & Shalet, S.M. A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. Clin. Endocrinol. 62, 623-627 (2005).
6. Laursen, T. et al. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults. J. Clin. Endocrinol. Metab. 86, 1222-1228 (2001).
7. Laursen, T., Jorgensen, J.O., Jakobsen, G., Hansen, B.L. & Christiansen, J.S. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients. J. Clin. Endocrinol. Metab. 80, 2410-2418 (1995).
8. Muller-Newen, G., Kohne, C. & Heinrich, P.C. Soluble receptors for cytokines and growth factors. Int. Arch. Allergy Immunol. 111, 99-106 (1996).
9. Baumann, G., Amburn, K.D. & Buchanan, T.A. The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J. Clin. Endocrinol. Metab. 64, 657-660 (1987).
10. Baumann, G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr. Rev. 12, 424-449 (1991).
11. Baumann, G., Shaw, M.A. & Buchanan, T.A. In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism 38, 330-333 (1989).
12. Clark, R.G. et al. Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat. Endocrinology 137, 4308-4315 (1996).
13. Baumann, G. Growth hormone binding protein - errant receptor or active player? Endocrinology 136, 377-378 (1995).
14. Ayling, R.M. et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat. Genet. 16, 13-14 (1997).
15. Ross, R.J. et al. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol. Endocrinol. 11, 265-273 (1997).
16. Ross, R.J.M. et al. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J. Clin. Endocrinol. Metab. 86, 1716-1723 (2001).
17. Cunningham, B.C. et al. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825 (1991).
18. Huston, J.S., Tai, M.S., McCartney, J., Keck, P. & Oppermann, H. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biophys. 22, 189-224 (1993).
19. Herington, A.C., Smith, A.I., Wallace, C. & Stevenson, J.L. Partial purification from human serum of a specific binding protein for human growth hormone. Mol. Cell. Endocrinol. 53, 203-209 (1987).
20. Frick, G.P., Tai, L.R., Baumbach, W.R. & Goodman, H.M. Tissue distribution, turnover, and glycosylation of the long and short growth hormone receptor isoforms in rat tissues. Endocrinology 139, 2824-2830 (1998).
21. Mannor, D.A., Winer, L.M., Shaw, M.A. & Baumann, G. Plasma growth hormone (GH)-binding proteins: effect on GH binding to receptors and GH action. J. Clin. Endocrinol. Metab. 73, 30-34 (1991).
22. Lim, L., Spencer, S.A., McKay, P. & Waters, M.J. Regulation of growth hormone (GH) bioactivity by a recombinant human GH-binding protein. Endocrinology 127, 1287-1291 (1990).
23. Haffner, D., Schaefer, F., Girard, J., Ritz, E. & Mehls, O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J. Clin. Invest. 93, 1163-1171 (1994).
24. Johnson, V. & Maack, T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am. J. Physiol. 233, F185-F196 (1977).
25. Veldhuis, J.D. et al. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J. Clin. Endocrinol. Metab. 87, 5737-5745 (2002).
26. Osborn, B.L. et al. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456, 149-158 (2002).
27. de Vos, A.M., Ultsch, M. & Kossiakoff, A.A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 (1992).